Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

News Conference News ESC 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

September 08, 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Boosting Potassium Helps Patients at High Risk for Ventricular Arrhythmias

News Conference News ESC 2025

Boosting Potassium Helps Patients at High Risk for Ventricular Arrhythmias

August 29, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

October 13, 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

News Conference News ESC 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

September 01, 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

August 31, 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

News Conference News ESC 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

August 26, 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

March 06, 2023

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.